Prestige Consumer Q2 adj EPS $1.07 beats prior year; raises FY adj EPS guidance to $4.54-$4.58

Prestige Consumer Healthcare Inc.

2026-Q2 EPS reported $1.81 revenue$523,644,000

Q2 revenue $274.1M (-3.4% YoY); diluted EPS $0.86 vs $1.09; adjusted EPS $1.07.
Raises FY2026 adjusted diluted EPS outlook to $4.54-$4.58 (high end of prior range).
Repurchased ~1.1M shares in Q2 for $75M; cumulative 1.6M shares in H1 for $109.8M.
Clear Eyes supply constraints drove OTC revenue decline; expects improvement in H2 via capacity rebuild.
Free cash flow guidance reaffirmed at $245M+; covenant leverage 2.4x.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.